- Home
- SCNX vs CYCN Comparison
SCNX vs CYCN Comparison
Compare SCNX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | CYCN |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 16.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SCNX | CYCN |
|---|---|---|
| Price | $0.38 | $3.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 689.8K | 32.4K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,831,778.00 | $2,074,000.00 |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.72 | 3.70 |
| 52 Week Low | $0.24 | $1.03 |
| 52 Week High | $2.60 | $8.48 |
Technical Indicators
Market Signals| Indicator | SCNX | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 64.21 |
| Support Level | $0.37 | $2.93 |
| Resistance Level | $0.43 | $4.47 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.73 | 65.53 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.